# Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6/2/06 - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hiv-1-resistance-data-attachment-to-the-guidance-draft-draft-guidance-this-draft-guidance-updates-the-final-guidance-posted-6206/5692d0bf-a0d8-4160-becb-4c084297e485

> FDA guidance document: Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6/2/06. Issue date: February 28, 2014. Get complete insights and analysis.

---

## Details

- Title: Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6/2/06
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2014-02-28
- Last Changed: 2021-01-26
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2014-D-0180">FDA-2014-D-0180</a>

## Related Documents

- [Drug Interaction Information in Human Prescription Drug and Biological Product Labeling](https://www.globalkeysolutions.net/guidances/guidance-document/drug-interaction-information-in-human-prescription-drug-and-biological-product-labeling/8bdf2914-581b-4e86-8a13-dacb0ef306c0)
- [Attachement - Qualification Process for Drug Development Tools: Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease](https://www.globalkeysolutions.net/guidances/guidance-document/attachement-qualification-process-for-drug-development-tools-qualification-of-exacerbations-of-chronic-pulmonary-disease-tool-for-measurement-of-symptoms-of-acute-bacterial-exacerbation-of-chronic-bronchitis-in-patients-with-chronic-obstructive-pulmonary-disease/88815054-17fc-4e46-a5c1-be7b0bad1ea9)
- [Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency Guidance for Submitting HCV Resistance Data -Attachment to Guidance](https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hcv-resistance-data-attachment-to-guidance/2f01091c-bdf0-477c-a276-df044ffd9889)